Glutaminergic Transmission in Autism : Molecular Imaging Exploration

Glutaminergic Transmission in Autism : Molecular Imaging Exploration

Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers

Inclusion Criteria:

• Male
• Between 18 years-old and 45 years-old
• Informed, written consent obtained from patient or his representant
• Subject with an affiliation to French social security
• For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS)
• For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1

Exclusion Criteria:

• Contraindications to MRI
• Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months
• Any unstable or uncontrolled disease, clinically significant
• Participation to an other experimental protocol with drug or irradiant exam
• Person under exclusion period because of previous participation to an other experimental protocol
• Person under temporary guardianship
• Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly
• For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSM-IV)